CC BY ND NC 4.0 · SynOpen 2018; 02(01): 0017-0024
DOI: 10.1055/s-0036-1591754
paper
Copyright with the author

Design, Synthesis, and Cytotoxic Evaluation of Etodolac-1,3,4-oxadiazole-1,2,3-triazole Molecules

Bhaskar Kummari
a  Centre for Chemical Sciences and Technology Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad-500085, T.S., India   Email: jayashreeaniredy@gmail.com
,
b  Natural Products Chemistry Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad-500007, T.S., India
,
Naveen Polkam
a  Centre for Chemical Sciences and Technology Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad-500085, T.S., India   Email: jayashreeaniredy@gmail.com
,
Shankaraiah Malthum
a  Centre for Chemical Sciences and Technology Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad-500085, T.S., India   Email: jayashreeaniredy@gmail.com
,
M. V. P. S. Vishnuvardhan
c  Medicinal chemistry and biotechnology, Indian Institute of Chemical Technology, Tarnaka, Hyderabad-500007, T.S., India
,
Jaya Shree Anireddy*
a  Centre for Chemical Sciences and Technology Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad-500085, T.S., India   Email: jayashreeaniredy@gmail.com
› Author Affiliations
Further Information

Publication History

Received: 03 November 2017

Accepted after revision: 24 December 2017

Publication Date:
29 January 2018 (online)

Abstract

A new series of etodolac-1,3,4-oxadiazole-1,2,3-triazole derivatives was designed and synthesized from commercially available starting materials by employing a simple synthetic sequence. The in vitro evaluation of the synthesized analogues displayed promising cytotoxic activity. Among the tested compounds 7c, 7l, and 7n exhibited highest cytotoxic activity against MCF-7 (breast), A549 (lung), and DU-145 (prostate) human cancer cell lines.

Supporting Information

 
  • References

  • 1 Kamath PR. Dhanya S. Abdul A. Jees A. Res. Chem. Intermed. 2016; 42: 5899
    • 2a Moulin A. Bibian M. Blayo AL. Habnouni SE. Martinez J. Fehrentz JA. Chem. Rev. 2010; 110: 1809
    • 2b Zhang K. Wang P. Xuan LN. Fu XY. Jing F. Li S. Liu YM. Chen BQ. Bioorg. Med. Chem. Lett. 2014; 24: 5154
    • 2c Kumar H. Javed SA. Khan SA. Amir M. Eur. J. Med. Chem. 2008; 43: 2688
    • 2d Gilani SJ. Khan SA. Siddiqui N. Bioorg. Med. Chem. Lett. 2010; 20: 4762
    • 2e Dawood KM. Farag AM. Abdel-Aziz HA. Heteroat. Chem. 2005; 16: 621
    • 2f Kalhor M. Mobinikhaledi A. Dadras A. Tohidpour M. J. Heterocycl. Chem. 2011; 48: 1366
    • 3a Deepak SM. Shashikant RP. Yalgatti MS. Int. J. Pharm. Chem. 2015; 5: 11
    • 3b Misra U. Hitkari A. Saxena AK. Gurtu S. Shanker K. Eur. J. Med. Chem. 1996; 31: 629
  • 4 Haider S. Alam MS. Hamid H. Inflammation Cell Signal 2014; 01: e95
    • 5a Soltis MJ. Yeh HJ. Cole KA. Whittaker N. Wersto RP. Kohn EC. Drug Metab. Dispos. 1996; 24: 799
    • 5b Balfour JA. Buckley MM. Drugs 1991; 42: 274
  • 6 Xu J.-M. Zhang E. Shi X.-J. Wang Y.-C. Yu B. Jiao W.-W. Guo Y.-Z. Liu HM. Eur. J. Med. Chem. 2014; 80: 593
    • 7a Schnitzer TJ. Constantine G. J. Rheumatol., Suppl. 1997; 47: 23
    • 7b Spencer-Green G. J. Rheumatol., Suppl. 1997; 47: 3
    • 8a Okamoto A. Shirakawa T. Bito T. Shigemura K. Hamada K. Gotoh A. Fujisawa M. Kawabata M. Urology 2008; 71: 156
    • 8b Kobayashi M. Nakamura S. Shibata K. Sahara N. Shigeno K. Shinjo K. Naito K. Ohnishi K. Eur. J. Haematol. 2005; 75: 212
    • 8c Carson DA. Cottam HB. Adachi S. Leoni LM. US 6,545,034, 2003
    • 8d Carson DA. Cottam HB. Adachi S. Leoni LM. US 7,105,560, 2006
    • 8e Carson DA. Cottam HB. Adachi S. Leoni LM. US 7,105, 561, 2006
    • 9a Shigemura K. Shirakawa T. Wada Y. Kamidono S. Fujisawa M. Gotoh A. Urology 2005; 66: 1239
    • 9b Kamijo T. Sato T. Nagatomi Y. Kitamura T. Int. J. Urol. 2001; 8: S35
    • 10a Galanakis D. Kourounakis AP. Tsiakitzis KC. Doulgkeris C. Rekka EA. Gavalas A. Kravaritou C. Charitos C. Kourounakis PN. Bioorg. Med. Chem. Lett. 2004; 14: 3639
    • 10b Kalgutkar AS. Marnett AB. Crews BC. Remmel RP. J. Med. Chem. 2000; 43: 2860
    • 10c Duflos M. Nourrisson MR. Brelet J. Courant J. Le Baut G. Grimaud N. Petit JY. Eur. J. Med. Chem. 2001; 36: 545
    • 10d Kalgutkar AS. Crews BC. Rowlinson SW. Garner C. Seibert K. Marnett LJ. Science 1998; 280: 1268
    • 11a Kobayashi M. Nakamura S. Shibata K. Sahara N. Shigeno K. Shinjo K. Naito K. Ohnishi K. Eur. J. Haematol. 2005; 75: 212
    • 11b Çıkla P. Özsavcı D. Bingöl-Özakpınar Ö. Şener A. Çevik Ö. Özbaş-Turan S. Akbuğa J. Şahin F. Küçükgüzel ŞG. Arch. Pharm. 2013; 346: 367
    • 11c Vyas S. Trivedi P. Chaturvedi SC. Acta Pol. Pharm. 2009; 66: 201
    • 11d Çıkla P. Özsavcı D. Bingöl-Özakpınar Ö. Şener A. Çevik Ö. Özbaş-Turan S. Akbuğa J. Şahin F. Küçükgüzel ŞG. Arch. Pharm. 2013; 346: 367
    • 11e Çıkla-Süzgün P. Kaushik-Basu N. Basu A. Arora P. Talele TT. Durmaz I. Çetin-Atalay R. Küçükgüzel ŞG. J. Enzyme Inhib. Med. Chem. 2015; 30: 778
  • 12 Bhaskar K. Naveen P. Perla R. Hasithashilpa A. Perumal Y. Jaya ShreeA. Sravanthi DG. Bathini NB. RSC Adv. 2017; 7: 23680
    • 13a Zhang Y. Qiao R.-Z. Xu P.-F. Zhang Z.-Y. Wang Q. Mao L.-M. Yu K.-B. J. Chin. Chem. Soc. 2002; 49: 369
    • 13b Dabholkar VV. Gandhale SN. Shinde NB. Pharma Chem. 2012; 4: 320
    • 13c Al-Talib M. Orabi SA. Al-Majdalawi S. Tashtoush H. Indian J. Heterocycl. Chem. 1999; 8: 183
    • 13d Tashtoush H. Abu-orabi S. Ta’an E. Al-Talib M. Asian J. Chem. 1999; 11: 444
  • 14 Kumar R. Yar MS. Rai AK. Chaturvedi S. Pharm. Lett. 2013; 5: 366
    • 15a Praveena KS. S. Durgaprasad S. Babu NS. Akkenapally A. Kumar CG. Deora GS. Murthy NY. S. Mukkanti K. Pal S. Bioorg. Chem. 2014; 53: 8
    • 15b Mareddy J. Nallapati SB. Anireddy J. Devi YP. Mangamoori LN. Kapavarapu R. Pal S. Bioorg. Med. Chem. Lett. 2013; 23: 6721